Skip to content

Xtant Medical Holdings XTNT Gain (Loss) on Disposition of Stock in Subsidiary

Gain (Loss) on Disposition of Stock in Subsidiary at other companies

Diodes logo
DiodesDIOD
$0
SiriusPoint logo
SiriusPointSPNT
$55.6M
FIP
FTAI Infrastructure Inc.FIP
$0-100%
WEBTOON Entertainment Inc. logo
WEBTOON Entertainment Inc.WBTN
$0+100%
Diodes logo
DiodesDIOD
$0
Cinemark Holdings logo
Cinemark HoldingsCNK
$6.9M

Other financials

Income statement

See full
Revenue$20.9M-36.5%
Gross profit$12.0M-40.9%
Operating income-$2.9M-375%
Net income-$3.1M-5,426%
EPS (diluted)-$0.02

Balance sheet

See full
Cash & equivalents$12.2M+124%
Total debt$15.0M-34.9%
Total equity$48.6M+10.8%
Total assets$78.0M-18.6%

Cash flow

See full
Operating cash flow-$2.1M-265%
CapEx$194.0K-83.7%
Free cash flow-$2.3M-2,753%

Valuation

See full
Market cap$59.05M-32.5%
Enterprise value$61.89M-41.5%
P/E32.3×
P/S0.5×-0.2×

Profitability

See full
Gross margin62.3%+4.2pp
Operating margin4.8%+2.8pp
Net margin1.5%+0.8pp
FCF margin6.4%+4.1pp

Returns & leverage

See full
Return on equity3.9%+2.1pp
Debt / equity0.3×-0.2×
Current ratio3.3×+1.0×

Where this comes from

Reported directly by Xtant Medical Holdings in its filing.

Tagged under the XBRL concept us-gaap:GainOrLossOnSaleOfStockInSubsidiary.

The official record: Xtant Medical Holdings’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xtant Medical Holdings's gain (loss) on disposition of stock in subsidiary.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xtant Medical Holdings's gain (loss) on disposition of stock in subsidiary?
Xtant Medical Holdings (XTNT) reported gain (loss) on disposition of stock in subsidiary of $820.25K in Q4 2025.
What does gain (loss) on disposition of stock in subsidiary mean?
The net profit or loss realized from the sale of equity interests in a subsidiary or business unit. This is classified as an operating adjustment to remove the non-recurring impact of divestiture gains or losses from core operating cash flow. It allows investors to distinguish between cash generated from ongoing business activities and cash generated from corporate restructuring.